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Abstract
Mutations in the tumor suppressor CYLD, known to be causative of cylindromas, were recently described in a subset of high-
risk (hr) HPV-positive head and neck squamous cell carcinomas (HNSCC). Pathologic and genetic characterization of these
CYLD-mutant carcinomas, however, remains limited. Here, we investigated whether CYLD mutations characterize a
histopathologically and genomically distinct subset of hrHPV-positive HNSCC. Comprehensive genomic profiling via
hybrid capture-based DNA sequencing was performed on 703 consecutive head and neck carcinomas with hrHPV
sequences, identifying 148 unique cases (21%) harboring CYLD mutations. Clinical data, pathology reports, and
histopathology were reviewed. CYLD mutations included homozygous deletions (n= 61/148; 41%), truncations (n= 52;
35%), missense (n= 26; 18%) and splice-site (n= 9; 6%) mutations, and in-frame deletion (n= 1; 1%). Among hrHPV-
positive HNSCC, the CYLD-mutant cohort showed substantially lower tumor mutational burden than CYLD-wildtype cases
(n= 555) (median 2.6 vs. 4.4 mut/Mb, p < 0.00001) and less frequent alterations in PIK3CA (11% vs. 34%, p < 0.0001),
KMT2D (1% vs. 16%, p < 0.0001), and FBXW7 (3% vs. 11%, p= 0.0018). Male predominance (94% vs. 87%), median age
(58 vs. 60 years), and detection of HPV16 (95% vs. 89%) were similar. On available histopathology, 70% of CYLD-mutant
HNSCC (98/141 cases) contained hyalinized material, consistent with basement membrane inclusions, within crowded
aggregates of tumor cells. Only 7% of CYLD-wildtype cases demonstrated this distinctive pattern (p < 0.0001).
Histopathologic patterns of CYLD-mutant HNSCC lacking basement membrane inclusions included nonkeratinizing (n=
22, 16%), predominantly nonkeratinizing (nonkeratinizing SCC with focal maturation; n= 10, 7%), and keratinizing (n=
11, 8%) patterns. The latter two groups showed significantly higher frequency of PTEN alterations compared with other
CYLD-mutant cases (38% [8/21] vs. 7% [8/120], p= 0.0004). Within our cohort of hrHPV-positive HNSCCs, CYLD
mutations were frequent (21%) and demonstrated distinctive clinical, histopathologic, and genomic features that may inform
future study of prognosis and treatment.
Introduction
The most recent World Health Organization classification of
head and neck tumors divides squamous cell carcinoma
(SCC) of the oropharynx into high-risk (hr) HPV-positive
and hrHPV-negative tumors [1]. Among hrHPV-positive
head and neck SCC (HNSCC), currently recognized mor-
phologic variants include papillary, adenosquamous, lym-
phoepithelioma-like, and basaloid subtypes [1]. In addition
to carcinomas of the oropharynx, hrHPV-positive SCC also
occurs at a lower frequency in other head and neck sites
including the sinonasal tract, oral cavity, and hypopharynx
and larynx [2].
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Nonkeratinizing histomorphology in SCC of the head
and neck strongly correlates with HPV infection [3]. The
basaloid subtype of oropharyngeal SCC, originally descri-
bed by Wain et al. [4], contains a basaloid component of
crowded cells with scant cytoplasm, often with thickened
basement membranes and inclusions of basement mem-
brane material, associated with foci of keratinization [4–6].
Some authors emphasize the “jigsaw-puzzle” pattern of
closely apposed tumor lobules, cystic spaces with myxoid
material, deposition of basement membrane material, and
abrupt keratinization to delineate the basaloid variant of
HNSCC from nonkeratinizing HPV-positive SCC, which
often displays “basaloid” cytomorphology (i.e., tumor cells
with scant cytoplasm and hyperchromatic nuclei) [7, 8].
Basaloid variant SCC with confirmed HPV positivity has
shown a better prognosis than HPV-negative basaloid var-
iant SCC [6, 9]. As such, some authorities emphasize HPV
testing in SCCs with histologic features of the basaloid
variant, to exclude the aggressive HPV-negative basaloid
variant [10].
Molecular genetic profiles of HNSCC differ by HPV
status [11, 12]. The genes most commonly altered in HPV-
negative HNSCC include TP53, CDKN2A, and CCDN1. In
contrast, HPV-positive HNSCC demonstrates a low rate of
TP53 and CDKN2A mutations, while PIK3CA mutations,
TRAF3 loss, and E2F1 amplifications are relatively com-
mon [11].
Mutations of CYLD, which encodes an enzyme regulator
of NF-κB, have been previously characterized as causative
of syndromic and sporadic cylindroma [13, 14] and were
recently described in HNSCC [15]. A recent study
demonstrated that HPV-positive HNSCC with mutations of
either CYLD or TRAF3, which has similar function to
CYLD, demonstrated increased NF-κB activity, harbored
HPV DNA in episomal form rather than integrated genomic
form, and correlated with improved patient survival [15].
Histopathologic features and comprehensive genomic
characteristics were not reported for this distinctive mole-
cular subtype of HNSCC.
Given recent work by our group that correlated CYLD
mutations in HPV-positive basaloid carcinomas of the anus
with cylindroma-like histologic features, low tumor muta-
tional burden (TMB), and low frequency of PIK3CA driver
mutations [16], we hypothesized that CYLD-mutant, HPV-
positive HNSCCs may have similarly distinctive histologic
and genomic features. In the current study, we retro-
spectively assessed HPV-positive head and neck carcinoma
samples analyzed by comprehensive genomic profiling
(CGP) for CYLD mutations. This analysis may enhance
tumor categorization and inform further correlations with
prognosis and potential therapeutic approaches to CYLD-
mutant tumors, such as recently investigated targeted inhi-
bitors for cylindromatosis [17, 18].
Materials and methods
Cohort and genomic analyses
Approval for this study, including a waiver of informed
consent and Health Insurance Portability and Accountability
Act waiver of individual authorization, was obtained from
the Western Institutional Review Board (Protocol No.
20152817). In the course of clinical care, physicians at
outside institutions sent tumor samples for CGP by our
Clinical Laboratory Improvement Amendments-certified,
College of American Pathologists-accredited laboratory
(Foundation Medicine, Inc., Cambridge, MA, USA). Here,
we searched our database of cases with CGP to identify all
HPV-positive head and neck carcinomas with CYLD
mutation versus CYLD-wildtype tumors. HPV status of each
case was determined via the sequencing platform, as
detailed below. We excluded adenocarcinomas and tumors
of the salivary glands. In brief, board-certified pathologists
confirmed pathologic diagnoses and tissue adequacy for all
cases on routine hematoxylin and eosin (H&E)-stained
slides before DNA extraction. Macrodissection of sections
was performed to achieve an estimated percent tumor nuclei
(%TN) above 20% in each case, where %TN is defined as
100 times the number of tumor cells divided by the total
number of nucleated cells. For genomic assessment, ≥60 ng
of DNA was extracted from 40-μm sections cut from for-
malin-fixed, paraffin-embedded tissue blocks containing
tumor. Adaptor ligation hybrid capture, utilizing the Foun-
dation One T7 baitset [19], was performed on the speci-
mens. Supplementary Table 1 lists all sequenced genes in
the T7 baitset. The Illumina HiSeq 4000 System was used
to perform sequencing of captured libraries to a mean exon
coverage depth of targeted regions of >500X. Sequences
were analyzed for genomic alterations, including short
variant alterations (base substitutions, insertions, and dele-
tions), copy number alterations (focal amplifications and
homozygous deletions), and select gene fusions or rear-
rangements [19–21]. For maximum sensitivity and specifi-
city of mutation detection in impure clinical specimens,
sequencing was previously optimized and validated to
detect base substitutions at a ≥5% mutant allele frequency,
indels with a ≥10% mutant allele frequency with ≥99%
accuracy, and fusions occurring within baited introns/exons
with >99% sensitivity [19]. TMB, quantified as mutations
per Mb, was assessed on 1.1 Mb of sequenced DNA [21].
Up to 114 loci were assessed for determination of micro-
satellite instability (MSI) [22]. De novo assembly of non-
human sequencing reads and comparison utilizing the basic
local alignment search tool for nucleotides (BLASTn)
against viral sequences in the comprehensive NCBI RefSeq
database was used to detect HPV DNA sequences. HPV
positivity was designated for cases with contigs ≥80
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nucleotides in length with ≥97% sequence identity to the
Refseq sequence identified by BLASTn. Evaluated HPV
types included HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42,
43, 44, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67,
68, 69, 70, 71, 72, 73, 81, 82, 83, 84, CP6108, and IS39.
HPV16, 18, 33, and 58 were designated hr, and HPV6 was
designated low-risk, as previously described [23].
Mutational signatures
The presence and quality of mutational signatures was
evaluated for all samples with at least 20 nondriver mis-
sense mutations. Signatures were assigned through analysis
of the trinucleotide context with profiling of the Sanger
COSMIC cancer mutational signatures [24]. A positive
signature required at least 40% of identified genomic
alterations to fit to a known mutational process: APOBEC
overexpression (C > T and C > G base substitutions),
exposure to UV light (C > T and CC > TT base substitutions
at dypirimidine sites), hypofunction of the BRCA tumor
suppressor (>3 base pair insertions or deletions with over-
lapping microhomology at breakpoint junctions), and
defects in mismatch repair (<3 base pair insertions and
deletions at mono/polynucleotide repeats) [24].
Germline prediction
Computational prediction of whether a particular CYLD
mutation was germline was performed using a previously
validated somatic-germline-zygosity algorithm [20]. This
technique aligns sequencing reads and mutant allele fre-
quencies for detected mutations and compares these to the
expected values generated by the copy number model [19].
Based on this comparison, the algorithm calculates a pre-
diction of whether the variant was germline, somatic, or
ambiguous [20].
Clinicopathologic analyses of head and neck
carcinomas with CYLD mutations
Outside institutional pathology reports that accompanied
each specimen sent to Foundation Medicine for CGP were
reviewed to collect clinicopathologic data, including patient
age, gender, tumor site, and AJCC stage (8th edition) [25].
H&E-stained sections from each available CYLD-mutant
hrHPV-positive carcinoma were assessed retrospectively by
three pathologists (EAW, JYT, MCM) for histologic fea-
tures, including growth pattern, deposition of basement
membrane material, squamous differentiation, necrosis, and
cytomorphology. The description of “basaloid” cytomor-
phology was applied to tumors composed of cells with scant
cytoplasm and hyperchromatic nuclei. The designation of
carcinomas with “cylindroma-like histopathologic features”
was assigned principally by the presence of inclusions of
hyalinized material, consistent with basement membrane
inclusions reminiscent of those seen in cylindroma, within
aggregates of carcinoma cells; however, additional histo-
logic features, described in the “Results,” were also com-
mon in this subgroup. The identification of keratinization
was based on the histologic presence of squamous pearls or
aggregates of cells with glassy, eosinophilic cytoplasm.
SCCs lacking basement membrane inclusions were classi-
fied into one of three categories: “non-keratinizing” for
SCCs lacking keratinization; “predominantly non-kerati-
nizing” for SCCs in which keratinization was present but
limited to small foci representing <10% of the examined
tumor area; and “keratinizing” for SCCs with keratinization
in ≥10% tumor area. Histopathology of CYLD-wildtype
hrHPV-positive carcinomas was reviewed for comparison.
Histopathologic assessment of all cases was limited to the
sequenced tissue, representing one block of tumor per case.
Reviewers were aware of the CYLD status when evaluating
the histologic features. Although immunohistochemical
slides were not available for retrospective review, we col-
lected immunohistochemical findings from pathology
reports.
Given the size of the cohort, Fisher’s exact test was used
for analyses of categorical data. For comparison of con-
tinuous parameters (age and TMB) between two groups, the
non-parametric Mann–Whitney U test was used. A two‐
tailed p value of <0.05 was considered statistically sig-
nificant. For multiple simultaneous comparisons, the Bon-
ferroni correction was applied.
Results
Clinicopathologic features of CYLD-mutant hrHPV-
positive head and neck carcinoma
In our database, we identified 703 distinct hrHPV-positive
head and neck carcinoma specimens, of which head and
neck adenocarcinoma and cases of salivary gland origin
were excluded as no HPV-positive CYLD-mutant cases
were identified in these groups. In total, 148 distinct cases
(21%) featured CYLD mutations. Compared with CYLD-
wildtype head and neck carcinomas (n= 555), CYLD-
mutant cases showed similar male predominance as
CYLD-wildtype hrHPV-positive head and neck carcinoma
(“CYLD-wildtype”; 94% [139/148] vs. 87% [484/555],
respectively, not significant with corrected p value;
Table 1), as well as median age (58 vs. 60 years, NS;
Table 1). The cohort of 148 CYLD-mutant carcinomas
encompassed 40 primary HNSCC, 1 primary-site recur-
rence, and 107 metastatic samples. The metastatic samples
were from the liver (n= 35/107; 33%), lung (n= 30; 28%),
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regional lymph nodes (n= 14; 13%), bone (n= 11; 10%),
distant soft tissue (n= 9; 8%), distant lymph nodes (n= 4;
4%), brain (n= 2; 2%), adrenal (n= 1; 1%), and small
intestine (n= 1; 1%). Compared with HPV-related CYLD-
wildtype head and neck carcinoma, CYLD-mutant cases
were sequenced much more frequently from liver samples
(24% [35/148] vs. 7% [37/555], p < 0.0001; Table 1). Of the
entire cohort of 148 CYLD-mutant carcinomas, known
primary sites included oropharynx (n= 121; including 51 at
the base of tongue, 51 tonsillar, 18 oropharynx not further
specified, and 1 soft palate), nasopharynx (n= 3), and
sinonasal tract (n= 1, which was an HPV16 positive case of
sphenoid sinus origin). The remaining 23 cases were
sequenced from metastatic samples, and the precise primary
tumor site within the head and neck was not further
specified.
Table 1 Comparative demographics, genomic alterations, and additional biomarkers of high-risk HPV-related head and neck carcinomas stratified
by CYLD mutation status.
CYLD-mutant CYLD-wildtype p*
Number of cases 148 555
% male 94% (139/148) 87% (484/555) 0.02
Median age (range) 58 (38–89) 60 (8–89+) 0.684
Cylindroma-like histopathology (%) 70% (98/141) 7% (34/459) <0.0001
Sequenced from liver metastasis (%) 24% (35/148) 7% (37/555) <0.0001
Sequenced from lung metastasis (%) 20% (30/148) 15% (83/555) 0.131
Median TMB (Q1–Q3; mut/Mb) 2.61 (1.74–3.48) 4.35 (2.61–7.83) <0.0001
HPV16 positive 95% (140/148) 89% (494/555) 0.043
MSI high 0% (0/138) <1% (2/513) 1.000
PI3K/AKT/mTOR pathway
PIK3CA 11% 34% <0.0001
KMT2Da 1% 16% <0.0001
FBXW7 3% 11% 0.0018
PTEN 12% 13% 0.679
SOX2a 2% 6% 0.085
STK11 2% 4% 0.442
Epigenetic regulation
KMT2C 5% 11% 0.037
EP300 5% 6% 0.840
DNA damage
TP53 4% 11% 0.008
BCL2L1 12% 5% 0.009
Single pass transmembrane receptor
NOTCH1 6% 8% 0.598
Cell cycle regulation
RB1 6% 7% 0.855
CDKN2A 1% 6% 0.019
CCND1 1% 3% 0.094
Receptor tyrosine kinase
FGFR3 1% 7% 0.004
ERBB2 1% 3% 0.390
EGFR 0% 2% 0.081
Non-receptor tyrosine kinase
SRC 5% 1% 0.015
RAS/MAPK pathway
KRAS 1% 2% 0.320
aLimited data in the literature on role in PI3K/AKT signaling.
*The Bonferroni correction for 27 simultaneous comparisons was applied; rows with a significant p value (<0.0019) are highlighted in bold.
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The CYLD-mutant carcinomas were clinically advanced.
By AJCC 8th edition criteria [25], documented cases (n=
141) were predominantly stage IV (n= 135; 96%), while
the remaining documented cases were stage II (n= 5) and
III (n= 1). Stage was unknown for seven cases.
HPV typing by CGP then BLASTn revealed that CYLD-
mutant and CYLD-wildtype HPV-positive carcinomas
showed similar HPV16 predominance (95% [140/148] vs.
89% [494/555], respectively, not significant with corrected
p value; Table 1). The remaining eight CYLD-mutant cases
contained HPV18 (n= 2), HPV33 (n= 4), or HPV35 (n=
2) sequences. CYLD-wildtype cases showed comparable
rates of HPV18 (5.0% [28/555], p= 0.064), HPV33 (2.5%
[14/555], p= 1.0), and HPV35 (2.0% [11/555], p= 1.0)
sequences detected.
In comparison with HPV-related CYLD-wildtype head and
neck carcinoma, CYLD-mutant cases were sequenced more
frequently from liver samples (24% [35/148] vs. 7% [37/
555], p < 0.0001) (Table 1). Sample frequency from other
sites, such as lung, was not statistically different between the
CYLD-mutant and CYLD-wildtype cohorts (Table 1).
Histopathologic features of CYLD-mutant hrHPV-
positive HNSCC
Retrospective histopathologic review of 141 available
CYLD-mutant cases, consisting of representative sections of
107 core or incisional biopsies and 34 excisional specimens,
revealed SCCs with multiple patterns. Histopathologic
patterns were grouped as follows: SCC with cylindroma-
like features, nonkeratinizing SCC, predominantly non-
keratinizing SCC, and keratinizing SCC.
The majority of CYLD-mutant SCCs (98 cases, 71%)
displayed cylindroma-like histologic features, defined
principally by the presence of inclusions of basement
membrane material within aggregates of tumor cells. All
cases, by definition for this subgroup, contained inclusions
of densely hyalinized material, typically globular, consistent
with basement membrane inclusions, which were occa-
sionally in continuity with surrounding thickened basement
membranes (Fig. 1). These basement membrane inclusions
were widely distributed in 52 cases (53% of 98; Fig. 1a, b)
and focal in 46 (47%) cases (Fig. 1c). Tumor necrosis was
present in 88 cases (90%; Fig. 1a, d–f). All cases were
composed of lobules of crowded tumor cells with generally
“basaloid” cytomorphology, with cells containing scant
cytoplasm and atypical nuclei. In total, 86 cases (88%)
contained closely apposed tumor lobules. Foci of squamous
differentiation, defined by keratin pearls or foci of aggre-
gated squamous cells with dense eosinophilic cytoplasm,
were present in 23 of these cases (23% of 98; Fig. 2a).
Squamous differentiation was focal in 19 cases and multi-
focal in 4 cases. Myxoid stroma (stromal mucinous mate-
rial) was present in 52 cases (53% of 98); in 36 cases, the
Fig. 1 CYLD-mutant hrHPV-positive squamous cell carcinomas of
the head and neck with cylindroma-like histopathologic features.
a, b Carcinoma, nonkeratinizing, with crowded aggregates of tumors
cells with comedonecrosis and round inclusions of basement mem-
brane material. Higher power examination (b) reveals focal mucinous
stromal material associated with the hyaline inclusions (H&E). (c and
inset) Carcinoma composed of closely admixed and irregular tumor
lobules with inclusions of basement membrane-like material and
consisting of cells with scant cytoplasm and hyperchromatic nuclei
(H&E). d Carcinoma with prominent basement membrane inclusions
and necrosis with somewhat paler chromatin than other examples
(H&E). e Carcinoma with closely apposed lobules with cribriform
arrangement containing hyaline membrane and myxoid material
(H&E). f Rare pattern of CYLD-mutant, HPV-positive carcinoma with
cribriform pattern, mucinous stromal material, and limited inclusions
of basement membrane material (H&E).
362 E. A. Williams et al.
myxoid material was directly admixed with the epithelial
proliferations, while the myxoid material was limited to
peritumoral fibrotic stroma in 16 cases. When associated
with tumor cells, the myxoid material tended to be either
interstitial or mixed with hyaline inclusions; only one case
showed discrete inclusions of myxoid material (Fig. 1f).
For comparison, histologic features of 459 available
cases of CYLD-wildtype, hrHPV-positive HNSCC were
reviewed. Only 34 CYLD-wildtype HNSCC cases (7%)
contained inclusions of basement membrane material. These
inclusions were widely distributed in only three cases and
focal in the other 31. In the context of this cohort of HPV-
positive HNSCC, basement membrane inclusions were
significantly associated with CYLD mutation (p < 0.0001;
Table 1).
Of the 43 CYLD-mutant cases lacking basement mem-
brane inclusions, histologic patterns were typical of HPV-
positive oropharyngeal SCC [3], with patterns of non-
keratinizing SCC, predominantly nonkeratinizing SCC
(nonkeratinizing SCC with focal maturation), and kerati-
nizing SCC (Fig. 2b–d).
Twenty-two SCCs (16%) were nonkeratinizing, lacking
apparent keratinization on the tissue examined. Of these
nonkeratinizing SCCs, 11 cases (50%) showed necrosis,
and deposition of myxoid material was present in 11 cases
(50%), which was limited to stroma in 2 cases.
Ten SCCs (7%) were predominantly nonkeratinizing,
with evidence of keratinization (squamous pearls or
aggregates of cells with glassy eosinophilic cytoplasm)
limited to small foci representing less than 10% of the
examined tumor area. Seven of these cases (70%) showed
necrosis, while six cases contained myxoid material, limited
to stroma in one case.
Eleven SCCs (8%) were keratinizing with abundant
squamous differentiation. Six cases showed necrosis, while
three contained myxoid material, limited to stroma in
two cases.
Review of immunohistochemical details in accompany-
ing pathology reports found that the CYLD-mutant
HNSCCs that had been evaluated by immunohistochemistry
were consistently positive for p16 (99%; 76/77 cases), p63
(100%: 54/54 cases), p40 (100%; 39/39 cases), and CK5/6
(93%: 53/57 cases diffusely positive, 3/57 focal positive).
CK7 was diffusely positive in only 2/21 CYLD-mutant
cases, focally positive in 2/21 cases, and negative in the
remaining 17 cases. CYLD-mutant HNSCCs were con-
sistently negative when stained for synaptophysin (n= 0/35
cases), chromogranin (n= 0/33), TTF1 (n= 0/23), CK20
(n= 0/15), and CDX2 (n= 0/7).
Comprehensive genomic profiling of CYLD-mutant
hrHPV-positive HNSCC
The set of CYLD mutations in our cohort consisted of
homozygous deletions (n= 61/148; 41%), nonsense muta-
tions (n= 29; 20%), truncating frameshifts (n= 18; 12%),
truncating rearrangements (n= 5; 3%; total truncating
mutations= 52/148; 35%), missense mutations (n= 26;
18%), splice-site mutations (n= 9; 6%), and in-frame
deletions (n= 1; 1%) (Fig. 3a, b). One CYLD-mutant
tumor had a missense mutation and a nonsense mutation
(Fig. 3a) and is counted in each group.
Truncating mutations occurred in exons 4 (n= 1), 5 (n=
8), 6 (n= 1), 8 (n= 1), 9 (n= 7), 10 (n= 2), 12 (n= 6), 13
(n= 3), 14 (n= 1), 15 (n= 1), 16 (n= 7), 17 (n= 3), 18
(n= 4), 19 (n= 2), and 20 (n= 5). Missense mutations
Fig. 2 CYLD-mutant, hrHPV-
positive squamous cell
carcinomas of the head and





and squamous morules and
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basaloid cytomorphology and
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occurred in exons 4 (n= 2), 5 (n= 1), 10 (n= 3), 11 (n=
3), 12 (n= 4), 13 (n= 4), 15 (n= 1), 16 (n= 2), 17 (n= 1),
18 (n= 3), and 19 (n= 1).
Figure 3a and Table 1 show the most frequent genomic
alterations outside the CYLD locus in CYLD-mutant versus
CYLD-wildtype HNSCC tumors. The CYLD-mutant group
showed substantially lower TMB and less frequent altera-
tions in PIK3CA, KTM2D, and FBXW7, all three of which
are involved in the PI3K-AKT-mTOR pathway (Table 1).
Alterations in PTCH1 and SMO were rare or absent from
the CYLD-mutant (1% and 0%, respectively) and CYLD-
wildtype (1% and 0%) groups.
CYLD-mutant cases with predominantly nonkeratiniz-
ing SCC (SCC with focal maturation) (n= 10) and kera-
tinizing SCC (n= 11) patterns showed significantly higher
frequency of PTEN alterations compared with other
CYLD-mutant cases, with four PTEN-mutant cases in each
histopathologic pattern (38% [8/21] vs. 7% [8/120], p=
0.0004; dark green and blue versus dark gray and light
green histology tiles in Fig. 3a). These cases also exhibited
a higher frequency of alterations in the adjacent FAS gene
(24% [5/21] vs. 3% [3/120], p= 0.0019). Demographics
and site of sequenced specimen (primary vs. metastases)
were similar between cases with each histologic pattern.
We found no significant genetic differences between
CYLD-mutant carcinomas with cylindroma-like features
(n= 98) versus CYLD-mutant nonkeratinizing SCC (n=
22) (dark gray versus light green histology tiles in Fig. 3a).
No CYLD-mutant or CYLD-wildtype cases demonstrated
the NFIB-MYB gene fusion typical of adenoid cystic
carcinoma.
Patients with CYLD-mutant tumors sequenced from pri-
mary (n= 41) vs. metastatic sites (n= 107) showed similar
age and sex. Cases sequenced from metastatic sites showed
a significantly elevated rate of BCL2L1 amplification
compared with primary-site tumor samples (16% [17/107]
vs. 2% [1/41], p= 0.0248), particularly in cases sequenced
from liver metastases (20%; 7/35 cases). Median TMB was
not significantly different between primary-site versus
metastatic tumor samples (1.7 vs. 2.6 mut/Mb, p= 0.072).
No identifiable genetic differences were seen between spe-
cific primary anatomic origins of HNSCC (oropharynx,
Fig. 3 Clinicopathologic features and molecular landscape of
HPV-positive CYLD-mutant head and neck squamous cell carci-
noma. a Summary of clinical features, histopathology, and molecular
alterations in CYLD-mutant head and neck carcinoma. b Schematic of
functional domains of CYLD (transcript NM_015247), to include
identified mutation sites. CYLD nonsense mutations (n= 29), frame-
shift mutations (n= 18), and truncating rearrangement site (n= 5) are
denoted by black, orange, and yellow bars, respectively (top of dia-
gram; length of bar~number of cases). Missense mutations (n= 25),
splice-site mutations (n= 9), and in-frame deletions (n= 1) are labeled
with black, orange, and yellow arrows, respectively (predominantly
lower diagram). In total, 61 cases with homozygous deletions in CYLD
are not shown. CAP cytoskeleton-associated proteins; P phosphor-
ylation region.
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nasopharynx, sinonasal tract), but the number of non-
oropharyngeal cases was limited.
Six CYLD-mutant cases underwent analysis for muta-
tional signatures. Five of these cases were identified with an
APOBEC signature. Of the available CYLD-wildtype cases,
208 underwent mutational signature analysis and showed a
similar frequency of the APOBEC signature (63%, n= 131/
208).
Comparison of cases with CYLD mutations within the
ubiquitin hydrolase domain (exons 12–20) versus outside
the protease domain (exons 4–11) revealed no significant
clinical, histologic, or genomic differences. Within our
CYLD-mutant cohort, cases with HPV16 sequences showed
no significant differences when compared with cases car-
rying other hrHPV reads (HPV18, HPV33, or HPV35),
although numbers in this latter group were limited.
Twenty of the 148 CYLD-mutant cases had available
SGZ algorithm data to predict germline status, and all 20
CYLD mutations were predicted to be somatic.
Comparison of CYLD-wildtype HNSCC with
cylindroma-like inclusions vs. those without these inclu-
sions revealed that cases with cylindroma-like features
showed significantly lower TMB (median 2.6 vs. 4.4 mut/
Mb, p= 0.0219), and a lower frequency of PIK3CA (12%
[4/34] vs. 35% [150/425], p= 0.0042), KMT2D (3% [1/34]
vs. 18% [76/425], p= 0.0284), and FBXW7 genomic
alterations (0% [0/34] vs. 13% [53/425], p= 0.0229). In
these parameters, CYLD-wildtype HNSCC with
cylindroma-like histologic features resembled CYLD-
mutant HNSCC, which often showed cylindroma-like fea-
tures. In addition, CYLD-wildtype HNSCC with
cylindroma-like histology showed a higher frequency of
NFKBIA truncating alterations (12% [4/34] vs. 1% [4/425],
p= 0.0014). No other significant differences between
CYLD-wildtype HNSCC with vs. without cylindroma-like
features were identified.
Discussion
Here, we report that the presence of CYLD mutation defines
a relatively frequent subset of HPV-related HNSCC that
exhibits histopathologic features reminiscent of cylindroma
and distinctive genomics. Our group recently demonstrated
an analogous subset of HPV-positive, CYLD-mutant basa-
loid anal carcinomas with cylindroma-like histologic fea-
tures [16]. In addition to similar histology, the HPV-positive
CYLD-mutant anal carcinoma and HPV-positive CYLD-
mutant head and neck carcinoma share unusually low TMB,
low frequency of PIK3CA mutation, and a possible pre-
dilection for liver metastases.
Our current findings in HPV-positive HNSCCs correlate
and may unify previously reported genetic and
histopathologic findings for the CYLD-mutant subtype of
HNSCC. A recent detailed genetic study using TCGA data
found that one-third of HPV-positive SCCs of the head and
neck contained mutually exclusive mutations of either
CYLD or TRAF3, each of which is normally an endogenous
inhibitor of NF-kB. Thus, these mutations were found to
upregulate NF-kB activity [15]. HPV-positive SCCs with
these mutations demonstrated several additional distinctive
features, including HPV DNA in episomal form, rather than
chromosomally integrated, and high levels of mRNAs
associated with motility and proliferation. These CYLD- and
TRAF3-mutant cases also showed improved clinical survi-
val compared with HPV-positive HNSCC tumors lacking
mutations in these genes. TMB was not reported. Status of
the PIK3CA gene was examined in 36 HPV-positive
HNSCC tumors (4 CYLD-mutant, 9 TRAF3-mutant, 23
CYLD-wildtype/TRAF3-wildtype), and PIK3CA mutations
tended to be mutually exclusive from CYLD/TRAF3 muta-
tions. While this detailed study did not report histopathol-
ogy, our series correlates HPV-positive, CYLD-mutant
SCCs in this anatomic location with cylindroma-like his-
tologic features, particularly the presence of basement
membrane inclusions.
Earlier mRNA expression profiling and cluster analysis
[26], as well as RNA sequencing studies [27], identified two
distinct subtypes of HPV-positive HNSCC characterized by
differential mRNA expression, copy number alterations,
HPV DNA integration into host chromosomes, and fre-
quency of PIK3CA mutations. One subtype (termed HPV-
classical or HPV-keratinocyte, HPV-KRT) was character-
ized by expression of genes in keratinocyte differentiation,
high levels of host chromosomal integration of HPV DNA,
gain of chromosome 3q, frequent PIK3CA mutations, and
keratinization on histopathology. The other subtype (termed
HPV-immune response, HPV-IMU) was characterized by
expression of genes implicated in immune responses and
mesenchymal differentiation, low frequency of host chro-
mosomal integration of HPV DNA, infrequent PIK3CA
mutations, loss of chromosome 16q, and infrequent kerati-
nization [26, 27]. Interestingly, CYLD, which was listed in
the supplemental data of reference [27] along with a large
number of other genes on chromosome 16q, showed
somewhat decreased expression in the HPV-IMU group
[27]. Correlating these prior studies [15, 26, 27] with our
current findings, we note that our cohort of HPV-positive,
CYLD-mutant HNSCCs shares some key features with the
HPV-IMU subtype of HNSCC. In particular, we found that
PIK3CA mutations are significantly less frequent in CYLD-
mutant than in CYLD-wildtype HPV-positive HNSCC, and
that the majority of these cases demonstrate histopathologic
features of crowded tumor cell aggregates with basement
membrane inclusions and limited keratinization (Fig. 1). In
addition, as noted above, Hajek et al. showed that CYLD-
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mutant HNSCC generally lacked chromosomally integrated
HPV DNA [15], another feature of the HPV-IMU subtype
of HNSCC [26, 27].
From a morphologic standpoint, many cases in our
cohort of HPV-positive, CYLD-mutant HNSCC display
histopathologic features of the basaloid variant of HNSCC
[4–6], suggesting that CYLD mutation may be a marker of
HPV-positive basaloid variant SCC. Basaloid SCC is
composed of crowded aggregates of cells with scant cyto-
plasm and with associated glassy eosinophilic material
surrounding tumor lobules and entrapped as small round
inclusions, variably termed “hyalinosis” or “hyaline stromal
cores.” The jigsaw puzzle-like pattern of closely situated
irregular lobules of tumor cells and the presence of hyaline
material deposition have been emphasized as features that
distinguish the basaloid variant of SCC from the more
common nonkeratinizing HPV-associated HNSCC
[6, 8, 28]. In a classic study of ten basaloid SCCs of the
tongue, hypopharynx, and larynx, Wain et al. defined
basaloid SCC as an admixture of basaloid and squamous
foci: basaloid areas consisted of densely arranged small
cells with scant cytoplasm showing lobular growth, small
cystic spaces containing myxoid material, and collections of
hyaline material, while squamous zones manifested as either
surface SCC in situ or an invasive component with typical
keratinizing features such as keratin pearls and prominent
intercellular bridges [4]. Some cases displayed a cribriform
pattern of epithelial cells with matrix material likened to
adenoid cystic carcinoma. By electron microscopy, cystic
spaces contained either loose granules or replicated base-
ment membrane material. In a later study of 40 similar
cases, Banks et al. identified the hyaline material sur-
rounding and within tumor lobules in approximately two
thirds of cases and further noted the frequent presence of
comedonecrosis [5]. Comparative study of oropharyngeal
and laryngeal/hypopharyngeal basaloid SCCs has shown
similar histologic features, including deposits of hyaline
material and necrosis [29]. To the authors’ knowledge,
CYLD status has not been reported previously for histo-
pathologically well-characterized subtypes of HNSCC [4–6,
29, 30].
The association of histopathologic features of the basa-
loid variant of SCC, particularly hyaline deposition, with
CYLD mutation suggests a novel correlation between gen-
otype and histologic phenotype in HNSCC. Our impression,
especially in light of CYLD mutation, the fundamental
alteration in familial and sporadic cylindromas [13, 14], is
that the deposition of this hyalinized basement membrane
material most resembles that seen in cylindroma. To the
authors’ knowledge, study of genomic alterations within the
basaloid variant of HNSCC is limited to a 2004 study of
HNSCC subtypes, including seven basaloid carcinomas,
using microsatellite markers which found that basaloid SCC
tended to show loss of heterozygosity at loci on 9p and 11q
[30]. Interestingly, CYLD-wildtype carcinomas with
cylindroma-like basement membrane inclusions showed
strikingly similar genomics to CYLD-mutant cases, with
similarly low TMB and significantly less frequent altera-
tions in PIK3CA, KMT2D, and FBXW7. Furthermore, these
cases were enriched for inactivating alterations in NF-
kappa-B inhibitor alpha (NFKBIA), leading us to consider
that cylindroma-like features in HNSCC may be associated
with non-CYLD mutations that activate related pathways.
These potential mechanisms of histogenesis, including
TRAF3, which was not sequenced in this study, require
further investigation.
Studies of the prognosis of basaloid SCC of the head and
neck have found variable results, ranging from worse to
improved prognosis for the basaloid subtype [31–34]. These
studies are complicated, however, by the variable presence
of HPV infection, which is common in the oropharynx and
which plays an important role in prognosis of HNSCC
[6, 9]. Furthermore, some of these prognostic studies did
not clearly delineate nonkeratinizing oropharyngeal SCC,
sometimes called “basaloid” SCC in earlier studies, from
the bona fide basaloid variant of SCC.
With respect to HPV infection among basaloid SCCs of
the head and neck, Begum et al. found that 76% of basaloid
SCCs occurring in the oropharynx were HPV-positive while
nonoropharyngeal cases (hypopharynx, larynx, oral, and
sinonasal) were rarely positive for HPV [9]. Chernock et al.
similarly demonstrated consistent HPV positivity by in situ
hybridization among basaloid SCCs occurring in the oro-
pharynx, while laryngeal and hypopharyngeal cases were
consistently negative [6]. Both studies found that HPV-
positive cases have improved prognosis compared to HPV-
negative cases [6, 9]. The finding by Hajek et al. [15] that
HPV-positive, CYLD-mutant HNSCCs demonstrate a more
favorable prognosis than CYLD-wild-type cases suggests
that CYLD mutation, or potentially the surrogate of corre-
lated histopathologic features, may inform the clinical
phenotype of HPV-positive HNSCC.
CYLD, a de-ubiquitinating enzyme, suppresses both the
NF-κB pathway [35, 36] and the c-Jun N-terminal kinase
pathway [37–39]. Experimental models have shown that
CYLD loss promotes aggressive behavior in various
malignancies, including cutaneous SCC [40], pancreatic
carcinoma [41], and hepatocellular carcinoma [39]. CYLD
mutation has been most extensively studied in the context of
cutaneous cylindromas in both syndromic manifestations,
such as Brooke–Spiegler syndrome, and sporadic tumors
[13]. A variety of mutations of CYLD have been char-
acterized, typically resulting in truncation of the encoded
enzyme [14, 42–44].
Morphologically similar lesions, such as adenoid cystic
carcinoma or salivary basal cell adenocarcinoma, may arise
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in the oral cavity and oropharynx [45, 46], necessitating
awareness of oropharyngeal SCC variants, including those
with cylindroma-like features and CYLD mutation. The
histopathologic presence of necrosis, mitotic activity, and
nuclear pleomorphism favors basaloid variant SCC, and by
analogy the cylindroma-like carcinoma described here, over
adenoid cystic carcinoma [47].
Basal cell adenocarcinoma, which usually arises in the
parotid gland but may develop in minor salivary glands,
shares with the CYLD-mutant HNSCCs in this study several
features including basaloid cellular composition, increased
basement membrane material with inclusions, and, as sug-
gested here, CYLD mutation. Both tumor types also display
peripheral palisading of nuclei and foci of necrosis [48]. A
recent study identified CYLD mutations within both basal
cell adenomas and basal cell adenocarcinomas, perhaps
accounting for some of the morphologic overlap with the
cases in this current study [49]. Another study found
CTNNB1 mutations in basal cell adenomas and, among
other alterations, focal CYLD deletion and biallelic inacti-
vation of NFKBIA in a case of basal cell adenocarcinoma
[50]. Although few cases of HPV testing of basal cell
adenocarcinoma have been reported, rare tested cases have
been HPV-negative [51], contrasting the HNSCC cases in
this study. Furthermore, basaloid SCCs are generally
negative for CK7 and CD117, aiding in the distinction of
basal cell adenocarcinoma of the salivary gland [47].
By immunohistochemistry, basaloid variant SCC of the
head and neck is p63 positive and usually positive for
keratins, albeit sometimes focally [52]. Tumors are negative
for synaptophysin and chromogranin, which can be useful
for distinguishing basaloid SCC from small cell carcinoma
[10, 52]. The positivity for p63 and negativity for neu-
roendocrine markers also distinguishes basaloid SCC from
the rare entity of HPV-associated neuroendocrine carci-
noma of the oropharynx, which has the opposite immuno-
phenotype [53, 54]. Interestingly, a recent study of basaloid
SCC showed that a majority of tumors were positive for
SOX10 [55], a feature shared with most cylindromas
[56, 57], as well as some many other cutaneous adnexal
tumors and salivary gland tumors [58].
Cylindrocarcinomas of the skin are extremely rare and,
ultimately, dissimilar to basaloid HNSCC. While both are
carcinomas related to CYLD alterations, cylindrocarcinoma
consists of a malignant proliferation associated with a pre-
cursor cylindroma [59]. Although CYLD mutations have
been shown to be present in sporadic and syndromic
cylindromas [13], molecular characterization of cylin-
drocarcinomas, beyond their occasional association with
syndromes of germline CYLD mutation, is limited to char-
acterizations of TP53 alterations [60, 61].
In our assessment, basaloid carcinoma of the anus is
closely analogous to the CYLD-mutant oropharyngeal
carcinomas described in this study. In a 2005 report of
basaloid carcinomas of the anus, Chetty et al. noted that
the histologic features of basaloid cytomorphology,
comedonecrosis, and basement membrane inclusions were
shared by both the basaloid anal carcinomas and those
occurring in the oropharynx [62]. In addition to these
overlapping histopathologic changes, we further note that
these carcinomas from both sites show consistent CYLD
mutations, HPV positivity, low TMB, low frequency of
PIK3CA mutations, and likely propensity to metastasize to
the liver [16].
Limitations of our study primarily concern the nature of
our cases, which were drawn from a database of aggressive
and advanced stage (AJCC 8th edition) cancers sent for
analysis to search for potentially targetable genetic altera-
tions. Thus, indolent tumors or those cured by excision were
highly unlikely to be included. Follow-up data were also
limited, and thus future studies will be needed assess the
clinical course of these cancers, including prognostic fea-
tures and therapeutic responses. TRAF3 mutation and HPV
genomic integration were not evaluated in this study. In
addition, we were able to review only the histopathology of
the sequenced tissue, representing one block of tumor, most
often that of a core or incisional biopsy, potentially limiting
the ability to detect focal histologic features. Because the
initial histologic review focused on the CYLD-mutant
tumors to establish the range of histologic features, thereby
prompting a later comparative review of CYLD-wildtype
cases, CYLD mutational status was known at the time of
review, presenting the possibility of observer bias. Finally,
immunohistochemistry was not available for evaluation
beyond review of details from outside pathology reports.
In summary, we found that over one in five HPV-positive
head and neck carcinomas in our cohort carry CYLD
mutations, and that the presence of CYLD mutations defines
a subset of HNSCC tumors that often display cylindroma-
like histopathologic features and exhibit unusually low TMB
and infrequent alterations in PIK3CA. Characterization of
HPV-positive, CYLD-mutant carcinoma may assist in clas-
sification of HNSCC and potentially inform prognosis and
experimental therapies for the patients affected [17, 18], both
topics that will require additional study.
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